abemaciclib Search Results


abemaciclib cytostatic effects 5  (MedChemExpress)
95
MedChemExpress abemaciclib cytostatic effects 5
Abemaciclib Cytostatic Effects 5, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abemaciclib cytostatic effects 5/product/MedChemExpress
Average 95 stars, based on 1 article reviews
abemaciclib cytostatic effects 5 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
abemaciclib  (TargetMol)
94
TargetMol abemaciclib
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Abemaciclib, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abemaciclib/product/TargetMol
Average 94 stars, based on 1 article reviews
abemaciclib - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
abemaciclib  (Selleck Chemicals)
95
Selleck Chemicals abemaciclib
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Abemaciclib, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abemaciclib/product/Selleck Chemicals
Average 95 stars, based on 1 article reviews
abemaciclib - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
resource vendor identifier chemicals abemaciclib ly2835219 medchem express  (MedChemExpress)
95
MedChemExpress resource vendor identifier chemicals abemaciclib ly2835219 medchem express
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Resource Vendor Identifier Chemicals Abemaciclib Ly2835219 Medchem Express, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/resource vendor identifier chemicals abemaciclib ly2835219 medchem express/product/MedChemExpress
Average 95 stars, based on 1 article reviews
resource vendor identifier chemicals abemaciclib ly2835219 medchem express - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
abemaciclib mesylate  (Selleck Chemicals)
93
Selleck Chemicals abemaciclib mesylate
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Abemaciclib Mesylate, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abemaciclib mesylate/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
abemaciclib mesylate - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
cdk 4 6 inhibitor  (MedChemExpress)
92
MedChemExpress cdk 4 6 inhibitor
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk 4 6 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk 4 6 inhibitor/product/MedChemExpress
Average 92 stars, based on 1 article reviews
cdk 4 6 inhibitor - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
material abemaciclib metabolite m2  (MuseChem Chemicals)
92
MuseChem Chemicals material abemaciclib metabolite m2
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Material Abemaciclib Metabolite M2, supplied by MuseChem Chemicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/material abemaciclib metabolite m2/product/MuseChem Chemicals
Average 92 stars, based on 1 article reviews
material abemaciclib metabolite m2 - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
drug abemaciclib ly2835219 topscience cat  (TargetMol)
91
TargetMol drug abemaciclib ly2835219 topscience cat
Figure 5. The expression of CDK4 gene in P-Tex2 cluster is associated with the treatment outcomes of HPV+ head and neck squamous cell carcinoma (HNSCC) patients. (a) Single-cell transcriptomic profiling of HNSCC tumor microenvironment (TME). Twenty cell clusters are identified, colored by cell types. (b) The proliferation status of P-Tex and epithelial cells in violin plot. (c) The kernel density estimate distribution of proliferation markers (CDK4 and MKI67) and epithelial cancer cell markers (KRT15 and CD24) in uniform manifold approximation and projection (UMAP) plots. (d) The overall survival rate of HPV+/HPV- HNSCC patients in The Cancer Genome Atlas (TCGA) cohort related to the expression levels of CDK4 gene, adjusted for age and gender. (e) The proportion of P-Texs, T-Tex, and TEFF clusters in HPV+ and HPV- samples in TCGA cohort by using the deconvolution algorithm; statistics were assessed by Chi-square tests. Marker genes that were used to define cell clusters in (a) are deconvolved into the TCGA data to obtain the proportion of P-Texs, T-Tex, and Teff clusters in the TCGA cohort. (f) The cell viability of P-Tex and cancer epithelial cells assessed by CCK8 experiment after <t>Abemaciclib</t> treated in vitro. ***: p<0.001, **: p<0.01, *: p<0.05.
Drug Abemaciclib Ly2835219 Topscience Cat, supplied by TargetMol, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/drug abemaciclib ly2835219 topscience cat/product/TargetMol
Average 91 stars, based on 1 article reviews
drug abemaciclib ly2835219 topscience cat - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
abemaciclib metabolite m2  (MedChemExpress)
94
MedChemExpress abemaciclib metabolite m2
Figure 5. The expression of CDK4 gene in P-Tex2 cluster is associated with the treatment outcomes of HPV+ head and neck squamous cell carcinoma (HNSCC) patients. (a) Single-cell transcriptomic profiling of HNSCC tumor microenvironment (TME). Twenty cell clusters are identified, colored by cell types. (b) The proliferation status of P-Tex and epithelial cells in violin plot. (c) The kernel density estimate distribution of proliferation markers (CDK4 and MKI67) and epithelial cancer cell markers (KRT15 and CD24) in uniform manifold approximation and projection (UMAP) plots. (d) The overall survival rate of HPV+/HPV- HNSCC patients in The Cancer Genome Atlas (TCGA) cohort related to the expression levels of CDK4 gene, adjusted for age and gender. (e) The proportion of P-Texs, T-Tex, and TEFF clusters in HPV+ and HPV- samples in TCGA cohort by using the deconvolution algorithm; statistics were assessed by Chi-square tests. Marker genes that were used to define cell clusters in (a) are deconvolved into the TCGA data to obtain the proportion of P-Texs, T-Tex, and Teff clusters in the TCGA cohort. (f) The cell viability of P-Tex and cancer epithelial cells assessed by CCK8 experiment after <t>Abemaciclib</t> treated in vitro. ***: p<0.001, **: p<0.01, *: p<0.05.
Abemaciclib Metabolite M2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abemaciclib metabolite m2/product/MedChemExpress
Average 94 stars, based on 1 article reviews
abemaciclib metabolite m2 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
targetmol metabolites  (TargetMol)
93
TargetMol targetmol metabolites
Figure 5. The expression of CDK4 gene in P-Tex2 cluster is associated with the treatment outcomes of HPV+ head and neck squamous cell carcinoma (HNSCC) patients. (a) Single-cell transcriptomic profiling of HNSCC tumor microenvironment (TME). Twenty cell clusters are identified, colored by cell types. (b) The proliferation status of P-Tex and epithelial cells in violin plot. (c) The kernel density estimate distribution of proliferation markers (CDK4 and MKI67) and epithelial cancer cell markers (KRT15 and CD24) in uniform manifold approximation and projection (UMAP) plots. (d) The overall survival rate of HPV+/HPV- HNSCC patients in The Cancer Genome Atlas (TCGA) cohort related to the expression levels of CDK4 gene, adjusted for age and gender. (e) The proportion of P-Texs, T-Tex, and TEFF clusters in HPV+ and HPV- samples in TCGA cohort by using the deconvolution algorithm; statistics were assessed by Chi-square tests. Marker genes that were used to define cell clusters in (a) are deconvolved into the TCGA data to obtain the proportion of P-Texs, T-Tex, and Teff clusters in the TCGA cohort. (f) The cell viability of P-Tex and cancer epithelial cells assessed by CCK8 experiment after <t>Abemaciclib</t> treated in vitro. ***: p<0.001, **: p<0.01, *: p<0.05.
Targetmol Metabolites, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/targetmol metabolites/product/TargetMol
Average 93 stars, based on 1 article reviews
targetmol metabolites - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
molecule inhibitors  (MedChemExpress)
94
MedChemExpress molecule inhibitors
Figure 5. The expression of CDK4 gene in P-Tex2 cluster is associated with the treatment outcomes of HPV+ head and neck squamous cell carcinoma (HNSCC) patients. (a) Single-cell transcriptomic profiling of HNSCC tumor microenvironment (TME). Twenty cell clusters are identified, colored by cell types. (b) The proliferation status of P-Tex and epithelial cells in violin plot. (c) The kernel density estimate distribution of proliferation markers (CDK4 and MKI67) and epithelial cancer cell markers (KRT15 and CD24) in uniform manifold approximation and projection (UMAP) plots. (d) The overall survival rate of HPV+/HPV- HNSCC patients in The Cancer Genome Atlas (TCGA) cohort related to the expression levels of CDK4 gene, adjusted for age and gender. (e) The proportion of P-Texs, T-Tex, and TEFF clusters in HPV+ and HPV- samples in TCGA cohort by using the deconvolution algorithm; statistics were assessed by Chi-square tests. Marker genes that were used to define cell clusters in (a) are deconvolved into the TCGA data to obtain the proportion of P-Texs, T-Tex, and Teff clusters in the TCGA cohort. (f) The cell viability of P-Tex and cancer epithelial cells assessed by CCK8 experiment after <t>Abemaciclib</t> treated in vitro. ***: p<0.001, **: p<0.01, *: p<0.05.
Molecule Inhibitors, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecule inhibitors/product/MedChemExpress
Average 94 stars, based on 1 article reviews
molecule inhibitors - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
ly2835219  (Eli Lilly)
90
Eli Lilly ly2835219
Figure 5. The expression of CDK4 gene in P-Tex2 cluster is associated with the treatment outcomes of HPV+ head and neck squamous cell carcinoma (HNSCC) patients. (a) Single-cell transcriptomic profiling of HNSCC tumor microenvironment (TME). Twenty cell clusters are identified, colored by cell types. (b) The proliferation status of P-Tex and epithelial cells in violin plot. (c) The kernel density estimate distribution of proliferation markers (CDK4 and MKI67) and epithelial cancer cell markers (KRT15 and CD24) in uniform manifold approximation and projection (UMAP) plots. (d) The overall survival rate of HPV+/HPV- HNSCC patients in The Cancer Genome Atlas (TCGA) cohort related to the expression levels of CDK4 gene, adjusted for age and gender. (e) The proportion of P-Texs, T-Tex, and TEFF clusters in HPV+ and HPV- samples in TCGA cohort by using the deconvolution algorithm; statistics were assessed by Chi-square tests. Marker genes that were used to define cell clusters in (a) are deconvolved into the TCGA data to obtain the proportion of P-Texs, T-Tex, and Teff clusters in the TCGA cohort. (f) The cell viability of P-Tex and cancer epithelial cells assessed by CCK8 experiment after <t>Abemaciclib</t> treated in vitro. ***: p<0.001, **: p<0.01, *: p<0.05.
Ly2835219, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly2835219/product/Eli Lilly
Average 90 stars, based on 1 article reviews
ly2835219 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining abemaciclib, palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.

Journal: International Journal of Biological Sciences

Article Title: The Interaction of CircESR1 and HNRNPAB Regulates Cell Cycle Transition of Breast Cancer Cell

doi: 10.7150/ijbs.126014

Figure Lengend Snippet: Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining abemaciclib, palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.

Article Snippet: Tamoxifen (T6906), Fulvestrant (T2146), Abemaciclib (T2381), Palbociclib (T1785) and Ribociclib (T6199) were from Targetmol (Boston, USA).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Control, MTT Assay, Transfection, Concentration Assay, Injection, Negative Control, Staining, Derivative Assay, Two Tailed Test

Figure 5. The expression of CDK4 gene in P-Tex2 cluster is associated with the treatment outcomes of HPV+ head and neck squamous cell carcinoma (HNSCC) patients. (a) Single-cell transcriptomic profiling of HNSCC tumor microenvironment (TME). Twenty cell clusters are identified, colored by cell types. (b) The proliferation status of P-Tex and epithelial cells in violin plot. (c) The kernel density estimate distribution of proliferation markers (CDK4 and MKI67) and epithelial cancer cell markers (KRT15 and CD24) in uniform manifold approximation and projection (UMAP) plots. (d) The overall survival rate of HPV+/HPV- HNSCC patients in The Cancer Genome Atlas (TCGA) cohort related to the expression levels of CDK4 gene, adjusted for age and gender. (e) The proportion of P-Texs, T-Tex, and TEFF clusters in HPV+ and HPV- samples in TCGA cohort by using the deconvolution algorithm; statistics were assessed by Chi-square tests. Marker genes that were used to define cell clusters in (a) are deconvolved into the TCGA data to obtain the proportion of P-Texs, T-Tex, and Teff clusters in the TCGA cohort. (f) The cell viability of P-Tex and cancer epithelial cells assessed by CCK8 experiment after Abemaciclib treated in vitro. ***: p<0.001, **: p<0.01, *: p<0.05.

Journal: eLife

Article Title: Proliferative exhausted CD8+ T cells exacerbate long-lasting anti-tumor effects in human papillomavirus-positive head and neck squamous cell carcinoma

doi: 10.7554/elife.82705

Figure Lengend Snippet: Figure 5. The expression of CDK4 gene in P-Tex2 cluster is associated with the treatment outcomes of HPV+ head and neck squamous cell carcinoma (HNSCC) patients. (a) Single-cell transcriptomic profiling of HNSCC tumor microenvironment (TME). Twenty cell clusters are identified, colored by cell types. (b) The proliferation status of P-Tex and epithelial cells in violin plot. (c) The kernel density estimate distribution of proliferation markers (CDK4 and MKI67) and epithelial cancer cell markers (KRT15 and CD24) in uniform manifold approximation and projection (UMAP) plots. (d) The overall survival rate of HPV+/HPV- HNSCC patients in The Cancer Genome Atlas (TCGA) cohort related to the expression levels of CDK4 gene, adjusted for age and gender. (e) The proportion of P-Texs, T-Tex, and TEFF clusters in HPV+ and HPV- samples in TCGA cohort by using the deconvolution algorithm; statistics were assessed by Chi-square tests. Marker genes that were used to define cell clusters in (a) are deconvolved into the TCGA data to obtain the proportion of P-Texs, T-Tex, and Teff clusters in the TCGA cohort. (f) The cell viability of P-Tex and cancer epithelial cells assessed by CCK8 experiment after Abemaciclib treated in vitro. ***: p<0.001, **: p<0.01, *: p<0.05.

Article Snippet: Continued on next page Key resources table Reagent type (species) or resource Designation Source or reference Identifiers Additional information Sequence- based reagent Chromium Single Cell 5’ Gel Bead and Library Construction Kit 10× Genomics PN- 1000006; PN- 1000020 Sequence- based reagent Single Cell V(D)J Enrichment Kit Human T cell 10× Genomics PN- 1000005 Sequence- based reagent Visum Spatial Library Construction kit 10× Genomics PN- 1000184 Antibody FITC Mouse Anti- Human CD3 (mouse monoclonal) BD Pharmingen Cat#555332 FACS (0.8 μL per test) Antibody PE anti- human CD8a Antibody (mouse monoclonal) Cell Signaling Technology Cat#300908, Clone: HIT8a FACS (5 μL per test) Antibody Anti- human CD279 (PD- 1) (mouse monoclonal) Biolegend Cat#329920 FACS (5 μL per test) Antibody UBE2C (B- 8) PE (mouse monoclonal) Santacruz Cat#Sc271050 FACS (1:100) Antibody PE/Cyanine7 anti- human CD161 (mouse monoclonal) Biolegend Cat#339917 FACS (5 μL per test) Antibody Anti- CD8α (mouse monoclonal) Cell Signaling Technology Cat#70306S IHC (1:200) Antibody Anti- PD- 1 (Rabbit monoclonal) Cell Signaling Technology Cat#84,651T IHC (1:200) Antibody Anti- Ki67 (Rabbit monoclonal) Abcam Cat#ab16667, Clone: SP6 IHC (1:50) Antibody Anti- CDK4 (Rabbit monoclonal) Cell Signaling Technology Cat#12790 IHC (1:1000) Antibody Anti- CD24 (Rabbit Polyclonal) Proteintech Cat#10600- 1- AP IHC (1:200) Antibody Anti- HLA- DR (Rabbit monoclonal) Abcam Cat#ab92511 IHC (1:200) Antibody Anti- EpCAM (Rabbit monoclonal) Abcam Cat#ab223582, Clone: EPR20532- 225 IHC (1:500) Commercial assay or kit Cell Counting Kit- 8 MedChemExpress Cat#HY- K0301 Commercial assay or kit Manual Opal 7- Color IHC Kit Akoyabio Cat#NEL811001KT Cell line (Homo sapiens) Laryngeal carcinoma This paper FD- LSC- 1 Cell line maintained in State Key Laboratory of Biotherapy, West China Medical School, Sichuan University Chemical compound, drug Abemaciclib (LY2835219) Topscience Cat#T2381 Software, algorithm Cell Ranger count 10× Genomics v3.1.0 Software, algorithm Cell Ranger VDJ 10× Genomics v6.1.1 Software, algorithm Space Ranger 10× Genomics v2.0 Software, algorithm Seurat R RRID:SCR_007322 Software, algorithm monocle3 R RRID:SCR_018685 Software, algorithm CellChat R RRID:SCR_021946 Cheng, Qiu, Rao et al. eLife 2023;12:e82705.

Techniques: Expressing, Single Cell, Marker, In Vitro